DEFA14A: Lifecore Biomedical to Hold Special Stockholder Meeting to Remove Convertible Preferred Stock Exchange Cap

Lifecore Biomedical plans a special meeting on April 10, 2025, to seek stockholder approval for removing the exchange cap on its Series A Convertible Preferred Stock.

Summary

• Lifecore Biomedical, Inc. is planning to hold a special meeting of stockholders on April 10, 2025.
• The purpose of the meeting is to vote on a proposal to approve the issuance of common stock upon conversion of the company's Series A Convertible Preferred Stock.
• The proposal aims to comply with Nasdaq Listing Rule 5635(d).
• The approval would allow for the potential conversion of Convertible Preferred Stock beyond the current limit of 19.99% of the outstanding common stock prior to the issuance of the Convertible Preferred Stock.
• The maximum number of common shares that the Convertible Stock can be converted into is 6,056,284 shares based on the current conversion price.
• As of January 17, 2025, no holders of Lifecore's Convertible Preferred Stock have elected to convert their shares to Common Stock.
• The board of directors has set February 18, 2025, as the record date for stockholders entitled to vote at the Special Meeting.
• Lifecore plans to file a preliminary proxy statement with the SEC and will subsequently file a definitive proxy statement after SEC clearance.

Sentiment

Score: 6

Explanation: The announcement is fairly neutral. It outlines a procedural step related to existing agreements. While the potential for dilution exists, the company states it has no current plans for additional capital raising.

Positives

• The removal of the exchange cap could provide Lifecore with greater flexibility in managing its capital structure.
• The company states it currently has no plans to raise additional equity capital, suggesting the move is primarily to accommodate existing agreements.

Negatives

• The potential conversion of preferred stock could dilute existing common stockholders' ownership.

Risks

• The special meeting may not occur on the anticipated timeline.
• Changes in Lifecore's liquidity needs could impact the proposal.
• The proposal is subject to stockholder approval, and there is no guarantee it will pass.
• The company's future performance could be affected by risks outlined in its SEC filings, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Lifecore intends to file proxy materials with the SEC, including preliminary and definitive proxy statements, in connection with the Special Meeting.

Management Comments

• Lifecore currently has no plans to raise additional equity capital.

Industry Context

As a CDMO, Lifecore's actions are likely driven by the needs of its biopharmaceutical and biotechnology partners, and this move could be related to facilitating future collaborations or conversions related to existing agreements.

Comparison to Industry Standards

• Many CDMOs like Catalent, Thermo Fisher Scientific, and Lonza often use convertible preferred stock as a financing tool.
• The 19.99% limit is a common threshold that triggers shareholder approval requirements under Nasdaq rules, similar to what other listed companies face.
• Seeking shareholder approval to exceed this limit is a standard practice to provide flexibility in managing capital structure and potential dilution.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• The removal of the exchange cap could provide Lifecore with greater financial flexibility, potentially benefiting the company and its stakeholders in the long term.

Next Steps

• Lifecore will file a preliminary proxy statement with the SEC.
• Lifecore will file a definitive proxy statement with the SEC after clearance.
• Stockholders will vote on the proposal at the Special Meeting on April 10, 2025.

Key Dates

Keywords

Special Meeting, Convertible Preferred Stock, Common Stock, Lifecore Biomedical, Exchange Cap, Proxy Statement, Nasdaq Listing Rule 5635(d), Conversion